Drugs / Bomedemstat

Trials 16 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT07049939 Aug 2025 → Feb 2026 liver disorder Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT06596668 Oct 2024 → Feb 2025 Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 1 NCT05597306 Nov 2022 → Nov 2026 expected acute myeloid leukemia Terrence J Bradley, MD Recruiting No outcome recorded
Phase 1/23 trials
Phase 1/2 NCT05191797 Apr 2022 → Aug 2023 small cell lung carcinoma University of Washington Terminated No outcome recorded
Phase 1/2 NCT03136185 Jul 2017 → Mar 2022 myelofibrosis, primary myelofibrosis Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) Completed No outcome recorded
Phase 1/2 NCT02842827 Oct 2016 → Oct 2018 acute myeloid leukemia, myelodysplastic syndrome Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) Completed No outcome recorded
Phase 27 trials
Phase 2 NCT07424950 Nov 2026 → Nov 2028 expected myelofibrosis United Lincolnshire Hospitals NHS Trust Not yet recruiting No outcome recorded
Phase 2 NCT05558696 Sep 2023 → Mar 2025 acquired polycythemia vera Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) Completed No outcome recorded
Phase 2 NCT05569538 Dec 2022 → Dec 2024 myelofibrosis The University of Hong Kong Unknown No outcome recorded
Phase 2 NCT05223920 Dec 2021 → Aug 2024 essential thrombocythemia, primary myelofibrosis Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) Completed No outcome recorded
Phase 2 NCT04262141 Oct 2020 → Oct 2026 expected acquired polycythemia vera, essential thrombocythemia Terrence J Bradley, MD Active not recruiting No outcome recorded
Phase 2 NCT04254978 Sep 2020 → Mar 2023 essential thrombocythemia Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) Completed No outcome recorded
Phase 2 NCT04081220 Apr 2020 → Dec 2023 overdue essential thrombocythemia The University of Texas Health Science Center at San Antonio Active not recruiting No outcome recorded
Phase 33 trials
Phase 3 NCT06456346 Jul 2024 → Sep 2027 expected essential thrombocythemia Merck Sharp & Dohme LLC Active not recruiting No outcome recorded
Phase 3 NCT06351631 May 2024 → Dec 2034 expected acquired polycythemia vera, essential thrombocythemia, myelofibrosis, primary myelofibrosis Merck Sharp & Dohme LLC Recruiting No outcome recorded
Phase 3 NCT06079879 Dec 2023 → Jul 2027 expected essential thrombocythemia Merck Sharp & Dohme LLC Active not recruiting No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 17 sources stand behind the page.

FieldValueCited text
Known as Bomedemstat ClinicalTrials.gov intervention name — accepted as the source's own label NCT04254978
13

NCT02842827

NCT06596668

NCT05569538

NCT05597306

NCT06351631

NCT03136185

NCT06456346

NCT07424950

NCT05191797

NCT07049939

NCT05223920

NCT05558696

NCT06079879

Known as Bomedemstat ditosylate ChEMBL registry synonym — accepted as the source's own label CHEMBL4297289
Known as BOMEDEMSTAT TOSYLATE ChEMBL registry synonym — accepted as the source's own label CHEMBL4297289
Known as IMG-241 bis-tosylate salt ChEMBL registry synonym — accepted as the source's own label CHEMBL4297289
Known as IMG-7289 “This is an open-label, Phase 2 study of bomedemstat (IMG-7289), an inhibitor of lysine-specific demethylase 1 (LSD1), in combination with JAK inhibition (JAKi) in patients with...” NCT05569538
4

“An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms” NCT05223920

“Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis” NCT07424950

NCT04262141

NCT04081220

Known as IMG-7289 DITOSYLATE ChEMBL registry synonym — accepted as the source's own label CHEMBL4297289
Known as MK-3543 “An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms” NCT05223920
Action Inhibit “Lysine-specific histone demethylase 1 inhibitor” CHEMBL4297289
1

“lysine-specific demethylase 1 (LSD1) inhibitor” NCT02842827

Modality Small molecule CHEMBL4297289
Route Oral oral administration” NCT02842827
Target KDM1A “Lysine-specific histone demethylase 1 inhibitor” CHEMBL4297289